Assessing endometrial hyperplasia and carcinoma treated with progestin therapy

American Journal of Clinical Pathology

Volumn 138, Issue 4, 2012, Pages 524-534

  Mentrikoski, Mark J ^a   Shah, Akeesha A ^a   Hanley, Krisztina Z ^b   Atkins, Kristen A ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Complex atypical hyperplasia; Endometrial carcinoma; Progesterone treatment

Indexed keywords

GESTAGEN; LEVONORGESTREL; MEGESTROL ACETATE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL PRACTICE; COHORT ANALYSIS; COMPLEX ATYPICAL HYPERPLASIA; DRUG EFFICACY; ENDOMETRIUM BIOPSY; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEMALE; HISTOPATHOLOGY; HUMAN; HYSTERECTOMY; MALE; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT FAILURE; WELL DIFFERENTIATED ENDOMETRIAL CARCINOMA;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; COHORT STUDIES; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; HUMANS; LEVONORGESTREL; MEGESTROL ACETATE; MENOPAUSE; MIDDLE AGED; PROGNOSIS; TREATMENT FAILURE; YOUNG ADULT;

EID: 84866991018     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPM2TSDDF1MHBZ     Document Type: Article

References (23)

1. Farhi DC, Nosanchuk J, Silverberg SG. Endometrial adenocarcinoma in women under 25 years of age. Obstet Gynecol. 1986;68:741-745. (Pubitemid 17190209)
2. Kim MK, Yoon BS, Park H, et al. Conservative treatment with medroxyprogesterone acetate plus levonorgestrel intrauterine system for early-stage endometrial cancer in young women: pilot study. Int J Gynecol Cancer. 2011;21:673-677.
3. Laurelli G, Di Vagno G, Scaffa C, et al. Conservative treatment of early endometrial cancer: preliminary results of a pilot study. Gynecol Oncol. 2011;120:43-46.
4. Randall TC, Kurman RJ. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstet Gynecol. 1997;90:434-440. (Pubitemid 27357938)
5. Vergote I, Kjorstad K, Abeler V, et al. A randomized trial of adjuvant progestagen in early endometrial cancer. Cancer. 1989;64:1011-1016. (Pubitemid 19208849)
6. Giannopoulos T, Butler-Manuel S, Tailor A. Levonorgestrel-releasing intrauterine system (LNG-IUS) as a therapy for endometrial carcinoma. Gynecol Oncol. 2004;95:762-764. (Pubitemid 39592556)
7. Eftekhar Z, Izadi-Mood N, Yarandi F, et al. Efficacy of megestrol acetate (Megace) in the treatment of patients with early endometrial adenocarcinoma: our experiences with 21 patients. Int J Gynecol Cancer. 2009;19:249-252.
8. Ramirez PT, Frumovitz M, Bodurka DC, et al. Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review. Gynecol Oncol. 2004;95:133-138. (Pubitemid 39286288)
9. Sardi J, Anchezar Henry JP, Paniceres G, et al. Primary hormonal treatment for early endometrial carcinoma. Eur J Gynaecol Oncol. 1998;19:565-568. (Pubitemid 29008299)
10. Perino A, Quartararo P, Catinella E, et al. Treatment of endometrial hyperplasia with levonorgestrel releasing intrauterine devices. Acta Eur Fertil. 1987;18:137-140. (Pubitemid 17115859)
11. Thigpen JT, Brady MF, Alvarez RD, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol. 1999;17:1736-1744. (Pubitemid 29269242)
12. Ercan CM, Duru NK, Sakinci M, et al. Successful twin pregnancy achieved by assisted reproductive technology in a patient with polycystic ovary syndrome with complex atypical endometrial hyperplasia treated with levonorgestrel- releasing intrauterine system. Gynecol Endocrinol. 2010;26:125-128.
13. Wang CB, Wang CJ, Huang HJ, et al. Fertility-preserving treatment in young patients with endometrial adenocarcinoma. Cancer. 2002;94:2192-2198.
14. Mao Y, Wan X, Chen Y, et al. Outcomes of conservative therapy for young women with early endometrial adenocarcinoma. Fertil Steril. 2010;93:283-285.
15. Hahn HS, Yoon SG, Hong JS, et al. Conservative treatment with progestin and pregnancy outcomes in endometrial cancer. Int J Gynecol Cancer. 2009;19:1068-1073.
16. Shirali E, Yarandi F, Eftekhar Z, et al. Pregnancy outcome in patients with stage 1a endometrial adenocarcinoma, who conservatively treated with megestrol acetate. Arch Gynecol Obstet. 2012;285:791-795.
17. Deligdisch L. Hormonal pathology of the endometrium. Mod Pathol. 2000;13:285-294. (Pubitemid 30207513)
18. Chiva L, Lapuente F, Gonzalez-Cortijo L, et al. Sparing fertility in young patients with endometrial cancer. Gynecol Oncol. 2008;111(2 suppl):S101-S104.
19. Saegusa M, Okayasu I. Progesterone therapy for endometrial carcinoma reduces cell proliferation but does not alter apoptosis. Cancer. 1998;83:111-121. (Pubitemid 28299636)
20. Wheeler DT, Bristow RE, Kurman RJ. Histologic alterations in endometrial hyperplasia and well-differentiated carcinoma treated with progestins. Am J Surg Pathol. 2007;31:988-998. (Pubitemid 47012294)
21. Kamoi S, Ohaki Y, Mori O, et al. Determining best potential predictor during high-dose progestin therapy for early staged and well-differentiated endometrial adenocarcinoma using semiquantitative analysis based on image processing and immunohistochemistry. J Nihon Med Sch. 2011;78:84-95.
22. Norris HJ, Tavassoli FA, Kurman RJ. Endometrial hyperplasia and carcinoma. Diagnostic considerations. Am J Surg Pathol. 1983;7:839-847. (Pubitemid 14222470)
23. Tavassoeli FA, Devilee P. Pathology and Genetics: Tumors of the Breast and Female Genital Organs. 3rd ed. Lyons, France: IARC Press; 2003:4.